Omnicell, Inc. (NASDAQ:OMCL) Q4 2022 Earnings Call Transcript

Peter Kuipers: Yeah. Thanks. Thanks, Alex. Good question. Yeah. Of course, for the fourth quarter through the first quarter is always a little bit of seasonality. So that’s — you got to take that into account. And then we see product revenue modestly increasing through the year, mostly based on already contracted backlog that we had talked about in the prepared remarks and then the Advanced Services revenue and service revenue in totality is entirely vast majority of that is really based on the backlog of planned implementation, right? So that’s how we model it out and you can do it the same.

Randall Lipps: Yeah.

Allen Lutz: Got it. Thank you very much.

Randall Lipps: Thanks, Alex.

Operator: I would now like to turn the call over to Randall Lipps for closing remarks.

Randall Lipps: Well, thank you everyone for joining the call, and before I conclude the call, I wanted to give a shout out to the global Omnicell team for their hard work and resilience. I mean, throughout 2022, they did not waver on delivering exceptional service to our customers, pursuing our translational journey to an as-a-service business. It is a hard work and particularly supporting each other and the communities we serve. So on behalf of myself and the Board of Directors and the leadership team, I thank all of you, dear employees for the great work of 2022. We look forward to 2023 as we get back to that growth mode and get forward to transforming the pharmacy. Thanks, everyone.

Kathleen Nemeth: Thank you.

Operator: Thank you. Thank you, ladies and gentlemen. This does conclude today’s call. Thank you for your participation. You may now disconnect.